---
title: ADC Analytical & Bioanalytical Services | CBS
description: DAR profiling, conjugation variability, payload stability and ADC PK bioanalysis using HIC, HRMS and LC-MS/MS, from discovery support to clinical studies.
image: https://www.crystalbiosolutions.com/hubfs/Thumbnail-Crystal-Bio-Solutions-1.png
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

![Illustration of an antibody-drug conjugate](https://www.crystalbiosolutions.com/hs-fs/hubfs/Thumbnail-Crystal-Bio-Solutions-1.png?width=960&height=640&name=Thumbnail-Crystal-Bio-Solutions-1.png)

# ADC Programs: Integrated Analytical and Bioanalytical Support

Crystal Bio Solutions, part of Crystal Group, supports antibody-drug conjugate (ADC) programs with characterization and DAR analysis in Natick, Massachusetts, multi-analyte PK and immunogenicity assays in our GLP- and GCLP-compliant laboratory in Pleasanton, California, and PK/PD modeling by our clinical pharmacology team.

[![Let's talk](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/146565877/interactive-264126601418.png)](https://www.crystalbiosolutions.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKoPh7njRkndU2AR9uPQldr3kN7QXxCruhq9ZftVS3I8SbFeCTRptqXu0eyS1wx9stQHVj7aNUenAZiT2RfeRoc5FldbYwePaak8j4mogwD1DpJp5ooDDhjDqo9knjqpgOZSOH36BKEz1sMg3Ru5HNh3RTAjMWQXI48spuxyOYGzWuEgaSEPWHlW2tiYrn4q03tZBahkRGQoQQY121b5%2FGAhtRY&webInteractiveContentId=264126601418&portalId=146565877&hsLang=en)

![CBS orange-blue banner-1](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20orange-blue%20banner-1.png?width=2000&height=21&name=CBS%20orange-blue%20banner-1.png "CBS orange-blue banner-1")

DAR and Conjugation Analysis DAR distribution by HIC and reversed-phase chromatography, intact and reduced mass by HRMS, conjugation site and unconjugated antibody (D0). Natick, MA. Stability and Biotransformation Serum stability, in vivo DAR change and payload biotransformation using affinity capture with LC-MS. Natick, MA. Multi-Analyte PK Bioanalysis Total antibody, conjugated drug and free payload by ligand-binding, hybrid immunocapture LC-MS and LC-MS/MS. Pleasanton, CA. Immunogenicity Tiered ADA and NAb assays, including domain specificity where the payload or linker may be immunogenic. Pleasanton, CA. PK/PD Modeling Population PK/PD and exposure-response analysis across multiple ADC analytes by our clinical pharmacology team. Regulatory Support Regulatory strategy and authoring for IND and BLA submissions, delivered through our strategic partners.

![CBS orange banner-1](https://www.crystalbiosolutions.com/hs-fs/hubfs/website-assets/CBS%20orange%20banner-1.png?width=2000&height=24&name=CBS%20orange%20banner-1.png "CBS orange banner-1")

Related reading: [A generic LC-MS/MS solution for ADC PK bioanalysis](https://www.crystalbiosolutions.com/news-and-events/a-generic-lc-ms/ms-solution-for-adc-pk-bioanalysis?hsLang=en) · [ADC bioanalysis: DAR profiling and stability analysis](https://www.crystalbiosolutions.com/news-and-events/adc-bioanalysis-dar-profiling-and-stability-analysis?hsLang=en) · [How to choose a CRO for ADC bioanalysis](https://www.crystalbiosolutions.com/news-and-events/how-to-choose-a-cro-for-adc-bioanalysis?hsLang=en)

 

## Antibody-Drug Conjugates: Background

Antibody-drug conjugates (ADCs) use an antibody's binding to a target antigen to deliver a cytotoxic payload to tumor cells. Compared with unconjugated antibodies, they can deliver highly potent payloads to the tumor while limiting systemic exposure to the free drug.

 

ADCs are an established therapeutic class. More than ten ADCs have FDA approval, including Mylotarg, Besponsa, Adcetris, Kadcyla, Polivy, Padcev, Enhertu, Trodelvy, Tivdak, Zynlonta, Elahere and Datroway, with indications across lymphoma, leukemia, breast, urothelial, cervical and ovarian cancers. Datroway (datopotamab deruxtecan) was [approved by FDA on January 17, 2025](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast) for HR-positive, HER2-negative breast cancer. For current approval status and labeling, see Drugs@FDA.

## Antibody-Drug Conjugates (ADCs) Structure

 

ADCs connect a monoclonal antibody to a cytotoxic payload through a linker. The core components are the antibody, the linker and the payload.

 

ADC designs vary widely. Products directed at the same target can differ in epitope, conjugation site, linker chemistry and payload class, and these differences contribute to distinct safety and efficacy profiles.

 

Design considerations include:

 

- **Antibody:** a target with high tumor and low normal-tissue expression, suitable internalization, favorable PK, minimal nonspecific binding and low immunogenicity.
- **Conjugation site:** commonly lysine or cysteine residues, or engineered sites for site-specific conjugation.
- **Linker:** stable in circulation, with payload release inside target cells or in the tumor environment.
- **Payload:** high potency, a defined mechanism of action and chemistry compatible with conjugation.

[![Antibody-Drug-Candidate-Crystal-Bio-Solutions](https://www.crystalbiosolutions.com/hs-fs/hubfs/Antibody-Drug-Candidate-Crystal-Bio-Solutions.png?width=800&height=400&name=Antibody-Drug-Candidate-Crystal-Bio-Solutions.png "Antibody-Drug-Candidate-Crystal-Bio-Solutions")](https://www.crystalbiosolutions.com/news-and-events/a-generic-lc-ms/ms-solution-for-adc-pk-bioanalysis?hsLang=en)

## Mechanism of Action of ADC

 

After systemic administration, ADCs circulate with properties similar to the parent antibody. The antibody binds its antigen on tumor cells; the ADC is internalized and trafficked to lysosomes, where it is degraded or the linker is cleaved, releasing the payload. The payload then kills the cell, for example by damaging DNA or disrupting microtubules.

 

Linkers need to remain stable in circulation to limit off-target toxicity while allowing efficient release in target cells. Some ADCs are designed to release payload that can diffuse into neighboring cells, a ["bystander" effect](https://www.nature.com/articles/bjc2017367).

 

Cleavable linkers and membrane-permeable payloads often enable this effect, which can help in tumors with heterogeneous antigen expression. It also raises safety considerations, because free payload may reach normal tissues.

 

These processes shape ADC exposure and payload release, which is why ADC PK usually involves several analytes. See [Strategies for Antibody-Drug Conjugate Bioanalysis](https://www.crystalbiosolutions.com/news-and-events/strategies-for-antibody-drug-conjugates-bioanalysis?hsLang=en).

## Development History

 

The idea behind ADCs traces back to Paul Ehrlich's early-1900s concept of a "magic bullet." Early attempts in the 1950s linked antibodies to methotrexate. Progress accelerated with humanized antibodies, but challenges remained, including target selection, the balance between potency and toxicity, and immunogenicity.

 

- 2000: Mylotarg received FDA approval for acute myeloid leukemia; it was withdrawn in 2010 and reapproved in 2017 with a revised dose and indication.
- 2011: Adcetris approved.
- 2013: Kadcyla approved.
- 2017: Besponsa approved.
- 2019–2022: Polivy, Padcev, Enhertu, Trodelvy, Zynlonta, Tivdak and Elahere approved.
- 2025: Datroway approved (January 17) for HR-positive, HER2-negative breast cancer.

 

### Generations of ADCs

 

**First generation:**

Early ADCs used murine or chimeric antibodies and linkers that were often unstable in circulation. Products were heterogeneous, with variable DAR, which contributed to instability, aggregation and off-target toxicity.

**Second generation:**

Humanized antibodies improved targeting and more potent payloads increased activity, but many products still had narrow therapeutic windows, related in part to unconjugated antibody and high-DAR species that aggregate or clear rapidly.

**Third generation:**

Site-specific conjugation and newer linker-payloads aim for more uniform DAR, improved stability and PK, and a wider therapeutic window. The benefit is product-specific and established through characterization and clinical data.

## Core Technologies for Antibody-Drug Conjugate Development

 

Each component plays a defined role in how the ADC reaches tumor cells, releases its payload and performs consistently during development and clinical use.

 

**Target antigen selection**

ADC targets are ideally expressed on tumor cells with limited expression in normal tissues, to reduce on-target, off-tumor toxicity. Most are cell-surface antigens that are not extensively shed into circulation and that internalize after antibody binding, so the payload is delivered inside the cell. Some newer designs use non-internalizing targets and depend on extracellular payload release and a bystander effect.

 

**Antibody selection**

The antibody should deliver the payload selectively to tumor cells. Key features include high affinity for the target, a long *in vivo* half-life, low immunogenicity, low cross-reactivity and suitable sites for conjugation. Humanized and fully human antibodies are used to reduce immunogenicity. IgG1 is the scaffold of most approved ADCs; it has a long half-life and can mediate Fc-dependent effector functions such as ADCC. IgG4 can undergo Fab-arm exchange unless stabilized (for example, with an S228P hinge mutation).

 

**Linkers**

Linkers connect the payload to the antibody and need to be stable in circulation yet release the payload after internalization or in the tumor environment.

- **Non-cleavable linkers** (for example, thioether or maleimidocaproyl linkers) rely on lysosomal degradation of the antibody to release the active payload-linker-amino acid species; they tend to have lower off-target release but limited bystander effect.
- **Cleavable linkers** exploit differences between plasma and the intracellular or tumor environment, such as acidic pH, lysosomal proteases or reducing conditions. Protease-cleavable peptide linkers, such as valine-citrulline linkers cleaved by cathepsins, are widely used.

 

**Payloads**

Payloads need to be highly potent, stable in circulation, and have functional groups suitable for conjugation. Common classes include tubulin inhibitors (for example, MMAE and maytansinoids), DNA-damaging agents (for example, calicheamicin and PBD dimers) and topoisomerase I inhibitors (for example, deruxtecan (DXd), used in Enhertu and Datroway, and SN-38, used in Trodelvy).

 

**Conjugation methods**

Common approaches include conjugation to lysines, reduction of interchain disulfides to conjugate cysteines, and engineered site-specific methods. Lysine and interchain cysteine conjugation produce mixtures with a range of drug loads and attachment sites. Site-specific technologies, such as engineered cysteines, cysteine rebridging, non-natural amino acids, glycan remodeling and enzyme-mediated conjugation, can produce more homogeneous ADCs with a defined DAR. Any benefit in stability, PK or therapeutic window is product-specific and has to be shown through characterization and clinical data.

## The Future of Antibody-Drug Conjugates

 

Advances in antibody engineering, linker chemistry and payload design continue to widen the range of ADC designs in oncology. Emerging approaches aim to improve selectivity, tumor penetration and therapeutic window.

 

**1. Bispecific and biparatopic ADCs.**

Bispecific antibodies that engage two antigens, or two epitopes on the same antigen, can increase internalization and tumor selectivity. Examples include biparatopic HER2 designs and constructs that promote lysosomal trafficking, several of which are in clinical development.

**2. Dual-payload conjugates.**

Attaching two payloads with different mechanisms to one antibody may improve activity or address resistance. This approach requires more complex conjugation chemistry and characterization.

**3. New carrier formats.**

Smaller scaffolds such as antibody fragments or peptide-based carriers may improve penetration into solid tumors compared with full-length IgG, usually at the cost of a shorter half-life.

**4. Non-internalizing ADCs.**

Some platforms rely on payload release in the tumor microenvironment. The released drug can diffuse into cancer cells, which may support activity when internalization is limited.

**5. New payload classes.**

Beyond established classes, payloads with new mechanisms, such as immune-stimulating agents and targeted protein degraders, are being explored. Highly potent DNA-damaging payloads such as PBD dimers (used in Zynlonta) illustrate both the activity and the toxicity-management challenges of very potent payloads.

**6. Photoimmunotherapy as an ADC-like platform.**

Akalux (cetuximab sarotalocan, ASP-1929) links cetuximab to a near-infrared photoactivatable dye. Light activation causes rapid damage to the membranes of cancer cells bound by the antibody. It was approved in Japan in 2020 for unresectable locally advanced or recurrent head and neck cancer and is a complementary approach to conventional ADCs.

**Conclusions**

 

- ADCs combine antibody targeting with potent payloads and are an established class in oncology.
- Their development draws on antigen selection, linker and payload chemistry, conjugation methods, characterization and bioanalysis.
- Site-specific conjugation, new payloads and new formats continue to widen the range of ADC designs.

## How a CRO Can Help Antibody-Drug Conjugate Development?

[![Read More](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/146565877/interactive-305192293576.png)](https://www.crystalbiosolutions.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJKVw7xHkmKBOmRh3UTL3ZsmARRcgtxjsBOBP8RVZ3UVcJCFy29C3Zv2TCXeeRn5qTlkj3Bn9QaQs7Bb8ggHqZocRcJtyMIdTMJio31gwIMTPOuh7LkH%2FIQX%2BHRsgioFPrXM4hZ%2B1aTAMNjZzvHYQIQlkM%2F5gsHkx6TzmI0ccV%2FHnw02g2dXx7EpKQI7tsfGmWPHhX29o74v%2FNkvFIcH6PCLLyFGyJ%2BuOW5y%2BYfOYuermfhZmVmk97ujn1ziBWjgs0gQrrk9BWoNO3nEzJqwGlDESo36No%3D&webInteractiveContentId=305192293576&portalId=146565877&hsLang=en)

## Related Services

PK Assays for Biologics and ADCs Total antibody, conjugated drug and free payload assays. Extended Characterization by HRMS Intact mass, peptide mapping, PTMs, disulfides, glycans and charge variants. Biotransformation and In Vivo CQA Drug characterization in serum and other matrices after dosing. NAb and ADA Assays Immunogenicity assay development, validation and sample analysis.

## Frequently Asked Questions

 

### Which analytes are measured in ADC bioanalysis?

ADC PK typically requires several analytes: total antibody (conjugated and unconjugated), conjugated antibody or conjugated payload, and unconjugated (free) payload. Together they describe exposure, deconjugation in circulation and potential payload-related toxicity. Anti-drug antibodies are assessed separately as part of the immunogenicity strategy.

 

### How is the drug-to-antibody ratio (DAR) measured?

DAR and DAR distribution are commonly measured by hydrophobic interaction chromatography (HIC), reversed-phase chromatography, and intact or reduced mass analysis by high-resolution mass spectrometry. In biological matrix, affinity capture followed by LC-MS can track how DAR changes over time after dosing.

 

### Why does DAR change after dosing, and why does it matter?

Linker instability, payload loss or exchange, and payload metabolism can shift DAR in vivo. These changes affect exposure-response interpretation and safety margins. Serum stability and biotransformation studies help characterize these processes early in development.

 

### When is LC-MS preferred over ligand-binding assays for ADC PK?

LC-MS/MS is the standard approach for quantifying free payload and its metabolites. [Hybrid immunocapture LC-MS methods](https://www.crystalbiosolutions.com/news-and-events/hybrid-lc-ms/ms-for-large-molecule-and-adc-bioanalysis?hsLang=en) can quantify conjugated payload when specificity is critical. Ligand-binding assays remain widely used for total antibody and some conjugated-antibody formats.

 

### Which critical quality attributes are most important for ADCs?

Key ADC attributes include DAR distribution, the level of unconjugated antibody (D0), residual free drug-linker, conjugation site occupancy, aggregation, charge variants and payload stability. These attributes influence potency, safety and comparability after process changes.

 

### What should you look for in a CRO for ADC development?

An ADC partner should be able to measure multiple analytes (total antibody, conjugated drug and free payload), characterize DAR and conjugation-related attributes, assess linker-payload stability in biological matrix, and connect characterization data with PK and immunogenicity results. Experience preparing documentation for IND and BLA submissions is also important.

 

### How does Crystal Bio Solutions support ADC programs?

CBS combines ADC characterization and CMC analytical work at our [Natick, Massachusetts laboratory](https://www.crystalbiosolutions.com/locations/natick-biologics-cmc-analytical-lab?hsLang=en) with ADC bioanalysis (PK and immunogenicity) at our [Pleasanton, California laboratory](https://www.crystalbiosolutions.com/locations/pleasanton-bioanalysis-lab?hsLang=en), plus clinical pharmacology modeling, with regulatory support available through strategic partners, so analytical, bioanalytical and modeling data can be planned together.

 

## Have a Question?

Bring a real problem to our Chief Scientific Officers: one hour, at no cost, with a CDA in place first.

[Request a Free Consultation](https://www.crystalbiosolutions.com/scientific-consultation?hsLang=en)

## Related case studies

- [A Generic LC-MS/MS Solution for ADC PK Bioanalysis](https://www.crystalbiosolutions.com/news-and-events/a-generic-lc-ms/ms-solution-for-adc-pk-bioanalysis?hsLang=en): A generic LC-MS/MS workflow for total antibody and conjugated payload in ADC PK studies.

[See all case studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study?hsLang=en)

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#organization",
  "@type" : "Organization",
  "alternateName" : "CBS",
  "contactPoint" : [ {
    "@type" : "ContactPoint",
    "contactType" : "sales",
    "email" : "cbs_bd@crystalpharmatech.com",
    "url" : "https://www.crystalbiosolutions.com/contact-us"
  } ],
  "logo" : "https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20VI%20v2/CBS%20Logo.png",
  "name" : "Crystal Bio Solutions",
  "parentOrganization" : {
    "@type" : "Organization",
    "name" : "Crystal Group",
    "url" : "https://www.crystalpharmatech.com/"
  },
  "sameAs" : [ "https://www.linkedin.com/company/crystal-bio-solutions/" ],
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#website",
  "@type" : "WebSite",
  "inLanguage" : "en",
  "name" : "Crystal Bio Solutions",
  "publisher" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc/#webpage",
  "@type" : "WebPage",
  "about" : {
    "@id" : "https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc/#service"
  },
  "breadcrumb" : {
    "@id" : "https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc/#breadcrumb"
  },
  "description" : "DAR profiling, conjugation variability, payload stability and ADC PK bioanalysis using HIC, HRMS and LC-MS/MS, from discovery support to clinical studies.",
  "inLanguage" : "en",
  "isPartOf" : {
    "@id" : "https://www.crystalbiosolutions.com/#website"
  },
  "name" : "ADC Analytical & Bioanalytical Services | CBS",
  "url" : "https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc/#service",
  "@type" : "Service",
  "areaServed" : "Worldwide",
  "description" : "Characterization and bioanalysis for antibody-drug conjugates, including DAR and conjugation analysis, payload stability, total antibody, conjugated drug and free payload PK, and immunogenicity.",
  "hasOfferCatalog" : {
    "@type" : "OfferCatalog",
    "itemListElement" : [ {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "DAR and conjugation analysis (HIC, HRMS)"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Serum stability and biotransformation"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "ADC PK bioanalysis (LBA and LC-MS/MS)"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "ADC immunogenicity"
      }
    } ],
    "name" : "ADC Analytical and Bioanalytical Services"
  },
  "name" : "ADC Analytical and Bioanalytical Services",
  "provider" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc/#breadcrumb",
  "@type" : "BreadcrumbList",
  "itemListElement" : [ {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/",
    "name" : "Home",
    "position" : 1
  }, {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc",
    "name" : "Antibody-Drug Conjugates",
    "position" : 2
  } ]
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc/#faq",
  "@type" : "FAQPage",
  "mainEntity" : [ {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "ADC PK typically requires several analytes: total antibody (conjugated and unconjugated), conjugated antibody or conjugated payload, and unconjugated (free) payload. Together they describe exposure, deconjugation in circulation and potential payload-related toxicity. Anti-drug antibodies are assessed separately as part of the immunogenicity strategy."
    },
    "name" : "Which analytes are measured in ADC bioanalysis?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "DAR and DAR distribution are commonly measured by hydrophobic interaction chromatography (HIC), reversed-phase chromatography, and intact or reduced mass analysis by high-resolution mass spectrometry. In biological matrix, affinity capture followed by LC-MS can track how DAR changes over time after dosing."
    },
    "name" : "How is the drug-to-antibody ratio (DAR) measured?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Linker instability, payload loss or exchange, and payload metabolism can shift DAR in vivo. These changes affect exposure-response interpretation and safety margins. Serum stability and biotransformation studies help characterize these processes early in development."
    },
    "name" : "Why does DAR change after dosing, and why does it matter?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "LC-MS/MS is the standard approach for quantifying free payload and its metabolites. Hybrid immunocapture LC-MS methods can quantify conjugated payload when specificity is critical. Ligand-binding assays remain widely used for total antibody and some conjugated-antibody formats."
    },
    "name" : "When is LC-MS preferred over ligand-binding assays for ADC PK?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Key ADC attributes include DAR distribution, the level of unconjugated antibody (D0), residual free drug-linker, conjugation site occupancy, aggregation, charge variants and payload stability. These attributes influence potency, safety and comparability after process changes."
    },
    "name" : "Which critical quality attributes are most important for ADCs?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "An ADC partner should be able to measure multiple analytes (total antibody, conjugated drug and free payload), characterize DAR and conjugation-related attributes, assess linker-payload stability in biological matrix, and connect characterization data with PK and immunogenicity results. Experience preparing documentation for IND and BLA submissions is also important."
    },
    "name" : "What should you look for in a CRO for ADC development?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "CBS combines ADC characterization and CMC analytical work at our Natick, Massachusetts laboratory with ADC bioanalysis (PK and immunogenicity) at our Pleasanton, California laboratory, plus clinical pharmacology modeling, with regulatory support available through strategic partners, so analytical, bioanalytical and modeling data can be planned together."
    },
    "name" : "How does Crystal Bio Solutions support ADC programs?"
  } ],
  "url" : "https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc"
}
```